Royal Bank of Canada
STLNW

Royal Bank of Canada’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Royal Bank of Canada’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1
Closed – – 7875
2021
Q2 		$0 Buy
+1
New +$1 ﹤0.01% 7690

Other funds holding STLNW

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
USPCM
Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Royal Bank of Canada's STLNW Position: Q3 2021 in Review

Royal Bank of Canada sold out of Starling Oncology, Inc. Warrant (STLNW) in Q3 2021, closing a stake of 1 share.

Royal Bank of Canada first reported a position in STLNW in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 21 funds tracked by Wall St. Rank hold STLNW as of Q3 2021.

  • Royal Bank of Canada reported no remaining Starling Oncology, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Starling Oncology, Inc. Warrant share in Q3 2021.
  • Royal Bank of Canada first reported a position in Starling Oncology, Inc. Warrant in Q2 2021 and held it in 1 quarter.
  • Royal Bank of Canada's Starling Oncology, Inc. Warrant position peaked at $0 in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q3 2021.

Based on Royal Bank of Canada's 13F filing for Q3 2021, filed 15 Nov 2021.